MRL1: Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)
Study Details
Study Description
Brief Summary
This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Local, regional and distant tumor control rates [Up to 5 years post-radiotherapy]
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
- Disease-free and overall survival rates [Up to 5 years post-radiotherapy]
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
- Complication rates measured using the Common Toxicity Criteria for Adverse Events [Within 3 months of completing treatment]
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Secondary Outcome Measures
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR [Immediately after first MRL treatment visit]
Evaluate the patient experience during adaptive RT with the MRL using the Magnetic Resonance Imaging-Anxiety Questionnaire (MRI-AQ) which measures patient anxiety and tolerability of MR-related procedures
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR [Immediately after last MRL treatment visit]
Evaluate the patient experience during adaptive RT with the MRL using the EORTC satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7)
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR [d prior to starting treatment with the MRL, immediately after the last MRL treatment, at the first follow-up visit and annually thereafter during follow-up (up to 5 years post treatment)]
Evaluate the patient experience during adaptive RT with the MRL using -The EORTC QLQ C30 quality of life questionnaire
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR [each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment)]
Evaluate the patient experience during adaptive RT with the MRL using complete the Edmonton Symptom Assessment Scale revised version (ESAS-r)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
-
Planned to receive a course of MR-guided adaptive RT using the MRL
-
Ability to provide informed consent
Exclusion Criteria:
- Patients under 18 years old
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Princess Margaret Cancer Centre | Toronto | Ontario | Canada | M5G 2M9 |
Sponsors and Collaborators
- University Health Network, Toronto
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19-5843